Synthetic Biologics

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Synthetic Biologics (SYN) stock is soaring higher on heavy trading Tuesday even without a lack of news concerning the company. The post Synthetic Biologics: 6 Things for SYN Stock Investors to Know as the Biotech Skyrockets appeared first on InvestorPlace.

Synthetic Biologics: 6 Things for SYN Stock Investors to Know as the Biotech Skyrockets

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2020 Results - Earnings Call Transcript

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q2 2020 Results - Earnings Call Transcript

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2019 Results - Earnings Call Transcript

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2019 Results - Earnings Call Transcript

Synthetic Biologics, Inc (SYN) CEO Steven Shallcross on Q2 2019 Results - Earnings Call Transcript

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2019 Results - Earnings Call Transcript

News for Synthetic Biologics Stock (SYN)